Legal Opinion
Teva Pharmaceuticals USA, Inc. v. Azar, II
District Court, District of Columbia
Decided February 26, 2019No. Civil Action No. 2018-2394Published
1Opinion of the Court
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA TEVA PHARMACEUTICALS USA, INC., Plaintiff, v. Civil Action No. 18-2394 (RDM) ALEX M. AZAR, II, et al., Defendants. MEMORANDUM OPINION Plaintiff Teva Pharmaceuticals USA, Inc. (“Teva”) brings this action to obtain “immediate injunctive and declaratory relief” barring the Food and Drug Administration (“FDA”) from “depriving [Teva] of its statutory right to 180 days of marketing exclusivity for its generic version of the brand-name drug Restasis®.” Dkt. 1 at 2 (Compl. ¶ 1). Teva seeks a preliminary injunction. Dkt. 2. The FDA and…
2Cases cited38 opinions
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- Lujan v. Defenders of WildlifeSupreme Court of the United States · 1992
- Winter v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 2008
- Steel Co. v. Citizens for a Better EnvironmentSupreme Court of the United States · 1998
- Spokeo, Inc. v. RobinsSupreme Court of the United States · 2016
33 more not listed; retrieve them via the Exa API.